Puma Biotechnology, Inc. (Puma Biotechnology Company) Puma Biotechnology, Inc. (NASDAQ: PBYI) was founded in 2010 and is headquartered in Los Angeles, California, with 174 full-time employees. It is a biotechnology (biopharmaceutical) company focusing on The development and commercialization of cancer care improvement drugs and the licensing business for the further development of mid-term drug candidates.
Puma Biotechnology (PBYI):
Currently, Puma Biotechnology currently has 3 main drug candidates:
- PB272 neratinib (oral), used to treat early breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors and HER2 mutation non-amplified breast cancer;
- PB272 neratinib (intravenous injection);
- The company also developed PB357, an oral drug that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through epidermal growth factor receptors HER1, HER2 and HER4.
Puma Biotech has signed a license agreement with Pfizer for the development, production and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357 and certain related compounds.
In July 2017, Puma Biotechnology’s experimental breast cancer treatment drug was approved by the FDA for the treatment of early breast cancer patients with specific gene mutations.